A First-Of-Its-Kind Treatment For A Rare Respiratory Disorder
A Powerful Catalyst Is Only Months Away . . .
| Below is the most recent issue of Biotech Frontiers, from analyst Erez Kalir. In this issue, Erez provides one buy recommendation and a full review of the Biotech Frontiers portfolio. In addition to hosting Porter & Co. Biotech Frontiers on our website, we also make it available as a downloadable PDF. Subscribers can access this issue as a PDF on the “Issues & Updates” page here. If you have any questions, please give Lance, our Director of Customer Care, and his team a call at 888-610-8895 or internationally at 443-815-4447. Again, thanks for being part of Porter & Co. |
On the morning of September 11, 2001, Al-Qaeda terrorists hijacked two jets and flew them into the Twin Towers in New York City, taking the lives of 2,977 people and changing American history forever.
Raul Martinez was a sergeant with the New York City Police Department when the attacks took place. As a first responder, he rushed to the site of the disaster – and spent the next eight months at Ground Zero dealing with its aftermath. Describing those harrowing months, Martinez modestly explained, “I did what I had to do. I was just doing my job.”
Although we did not appreciate the implications at the time, the collapse of the Twin Towers unleashed a blend of jet fuel, concrete, steel, glass, paint, and other debris into the air, much of it in the form of tiny toxic matter. These particulates – which contained a multitude of known carcinogens such as asbestos, benzene, and beryllium – remained suspended in the air for weeks after. Few first responders understood the risks of breathing such air. A physician at UCLA School of Medicine would later remark, “Today, every single 9/11 recovery worker would be wearing an N-95. But nobody was wearing masks back then.”
Soon after his tour of duty at Ground Zero was complete, NYPD Sgt. Martinez – like thousands of other first responders who worked there – developed a dry, hacking cough that got progressively worse, eventually leaving him out of breath even when at rest. He was diagnosed with pulmonary sarcoidosis, a form of interstitial lung disease (“ILD”) where inflammation and scarring in the lungs can lead to devastating impairments in quality of life, and eventually to premature death.
Tragically, though both pulmonary sarcoidosis and the broader family of ILD have been known to medicine for decades, there are no cures and no truly effective therapies. Most patients are treated with corticosteroids, which can help manage symptoms in the short term and sometimes medium term but those steroids come with negative side effects in the long term. For the 9/11 first responders such as Sgt. Martinez and the hundreds of thousands of others who also suffer from ILD, the medical state of play has offered little hope.
This month, we’ll focus on a company that is changing all that. Its lead drug candidate promises to be a game-changing therapy both for pulmonary sarcoidosis and for the broader family of ILD to which it belongs.
This content is only available for paid members.
If you are interested in joining Porter & Co. either click the button below now or call our Customer Care team at 888-610-8895.